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Abstract
Background: Several reports have implied progressive increase of performance-enhancing drug (PED) use among Iranian athletes.
More importantly, most of the previous research in the Iranian population had mainly focused on the anabolic steroid abuse, and
ignored other agents.
Objectives: The aim of this study was to investigate the prevalence and characteristics of PED use among bodybuilding athletes in
Bushehr, south of Iran.
Methods: Four hundred and fifty three male bodybuilding athletes were recruited from Bushehr gyms between February and May
of 2015. Men were eligible to participate in the survey if they had regularly participated in the strength-training exercise (minimum
of 1 year and 4 hour/week). Data were collected via a face-to-face interview. The survey consisted of three separate parts including
demographic data, exercise pattern and PED use.
Results: According to this study, 234 (51.7%) of bodybuilding athletes had used PEDs. The PED users reported an average of 3.80±
4.52 agents’ use in their programs and they had used PEDs for the average of 3.24± 3.99 years. The most prevalent agents which
had been abused by the athletes were anabolic steroids (used by 185 athletes (79.4% of athletes). Furthermore, 110 (47%) of athletes
reported stimulant agents’ use during their routines. The most prevalent motivation for using PEDs was increasing muscle mass
that was reported by 164 (70.1%) of PED users. In addition, sexual and dermatologic effects were the most prevalent adverse effects
reported by the PED user athletes (114 (49.4%) and 103 (44.2%), respectively).
Conclusions: This study showed the high rate of PED use among recreational and professional Iranian bodybuilding athletes that
can expose them to the serious side effects of these agents.
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1. Background
Performance-enhancing drugs (PEDs) are pharmaco-
logic agents that athletes and non-athletes use to en-
hance performance or to become leaner or more mus-
cular (1). In sport, doping conventionally refers to the
use of PEDs, particularly those that are forbidden by the
international world anti-doping agency (WADA) (2). At
present, several categories of PEDs are popular among non-
competitive (recreational) and professional athletes. The
most prevalent agents abused by the athletes are anabolic
androgenic steroids (AASs) (1). In addition to AASs, other
hormones with potential anabolic activity like human
growth hormone (hGH), insulin and insulin-like growth
factor-1 (IGF-1) may be abused by the athletes. Recently,
the widespread abuse of stimulant agents such as Clen-
buterol (an α-adrenergic agonist), amphetamine deriva-
tives, ephedrine, pseudoephedrine and caffeine has been
documented among athletes (1, 3-5).
The use of PEDs in sports is not a new phenomenon and
dates back centuries; but it became much more popular by
the introduction of AASs (1, 6). Numerous investigations
have indicated high rate of PED use alongside lack of sci-
entific knowledge about these drugs all over the world (7).
In this regard, it was estimated that about 1% of the popu-
lation misuse AASs, while there are very limited data about
use of other types of PED in the different parts of the world
(6). Unfortunately, in recent years, widespread use of PEDs
among recreational rather than professional athletes has
led to the rapid rise of PED use in the different populations
around the world (8, 9).
Official and unofficial reports have indicated an in-
creasing rate of PED use among Iranian athletes (10, 11). In
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this regard, it was demonstrated that 63.3% of Iranian ath-
letes had a history of PED abuse (12). By considering seri-
ous adverse effects of PEDs, this high rate of PED abuse can
lead to dangerous consequences (10, 13). Therefore, there is
pressing need to investigate the prevalence and character-
istics of PED use in the different parts of Iran.
2. Objectives
Several reports demonstrated progressive rise of PED
use among the Iranian population. More importantly,
most of the previous research on the Iranians has mainly
focused on AAS abuse, and ignored other agents such as
stimulants, growth hormone (GH) and insulin. Moreover,
there are very limited reports about the age of the onset of
PED use, motivations for use, knowledge about side effects
in the Iranian professional and recreational athletes. For
these reasons, it is important to investigate the prevalence
of all types of PEDs in the Iranian population. Therefore,
the aim of this study was to investigate the prevalence and
characteristics of PED use among bodybuilding athletes in
Bushehr, south of Iran.
3. Methods
3.1. Participants and Study Design
The Research Ethics Committee of Bushehr University
of Medical Sciences approved the study and all parts of
the investigation were performed in accordance with the
declaration of Helsinki. Before introducing the survey, it
was emphasized that the collected information would be
kept confidential, and the results would be used collec-
tively only for research purposes. We presented detailed
information regarding the study objectives and methods
to the athletes. After knowing the survey details, the ath-
letes who agreed to participate in the study signed a writ-
ten consent form.
We randomly selected 11 gyms from Bushehr and con-
sulted with the gym managers for participation in the sur-
vey. From these clubs, we invited all bodybuilders who
were present at the club at the time of sampling. From all
who were invited, athletes who were eligible and agreed
to participate were included in the study. Men were eli-
gible to participate in the survey if they regularly partic-
ipated in strength-training exercise (minimum of 1 year
and 4 hour/week). Accordingly, 453 male bodybuilding ath-
letes were recruited from Bushehr gyms between February
and May of 2015.
3.2. Data Collection
Data were collected via a face-to-face interview using a
survey that took about 30 minutes for each participant. A
44-item survey mostly adopted from Ip and colleagues (14)
was used to assess several characteristics of men who par-
ticipated in the strength training. The survey consisted of
three separate sections. In the first section, we asked about
the demographic variables such as age, height, weight,
marital status, and educational level. In the second sec-
tion, we asked about exercise patterns (recreational or pro-
fessional athletes) and history, periodic check of health
condition, history of alcohol use, the history of violence,
PED use, familiarity with PED side effects, and the use of
dietary supplements other than PEDs. If the participants
had a history of PED use, we asked the 3rd part of sur-
vey. The last part consisted of motivations for PED use, PED
acquisition method, age of first PED use, the method of
acquisition of PEDs for the first time, the level of aware-
ness about PED effects and side effects before using. Other
than above-mentioned items, in the third section, we asked
about the type of drugs used, period of PED use, consul-
tation with pharmacist or general practitioner (GP), and
the subjective side effects. In this survey, a professional
athlete was defined as an individual participating in offi-
cial sport teams or championship tournaments. Moreover,
non-competitive athletes were considered as recreational
athletes.
3.3. Data Analysis
We reported continuous data as mean± SD, and cate-
gorical data as numbers and percentages of respondents,
mainly because of the descriptive nature of data. Indepen-
dent group t-test and one way analysis of variance (ANOVA)
test (for continuous data) and Chi square test (for categori-
cal data) were used to compare independent variables. For
continuous variables that deviated greatly from normality
(checked using Kolmogorov-Smirnov test) a nonparamet-
ric Wilcoxon rank test or Mann-Whitney U test were used.
Moreover, we used the Spearman correlation test to check
for relationship between variables. A p value of less than
0.05 was considered to indicate a statistically significant
difference. All statistical analyses were conducted using
SPSS software for Windows, version 23.
4. Results
4.1. Demographic
The mean age of the participants was 27.02 ± 6.00,
with an age range of 16 to 59 years. The participants were
mostly in the 20-29-year age group (251 of athletes (55.4%)).
It was shown that PED users were significantly older than
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non-user athletes were (t (451) = - 3.36, P = 0.001). Regard-
ing education, the majority of the athletes had an educa-
tional level of high school or higher (322 (93.2%)). Analy-
sis showed that the educational level of PED users was not
different from non-user athletes (X2 (2, N = 453) = 2.20, P =
0.33). Details of demographic characteristics are shown in
the Table 1.
Table 1. The Demographic Information of Male Bodybuilding (Performance Enhanc-
ing Drug Users and Non-Users) Athletes




Age 28.03± 6.13 25.95± 7.07 0.001
BMI (kg/m2) 26.36± 3.81 24.84± 3.37 0.000





20 (8.5) 11 (5)
High school 109 (46.6) 106 (48.4)
University 105 (44.9) 102 (46.6)
Obesity 0.000
Normal 77 (32.9) 126 (57.5)
Overweight 119 (50.9) 81 (37)
Obese 38 (16.2) 12 (5.5)
Marriage status
Single 159 (67.9) 161 (73.5) > 0.05
Married 75 (32.1) 58 (5.5)
Abbreviation: BMI, body mass index.
The PED users weighed significantly more (83.07 ±
12.86 vs. 77.68 ± 11.47 kg, t (451) = - 4.70, P = 0.000) with
a corresponding greater body mass index than the non-
users ([BMI] 26.36± 3.81 vs. 24.84± 3.37 kg/m2, respectively,
t (451) = - 4.48, P = 0.000). In addition, the prevalence of
overweightness and obesity were higher among PED users
in comparison to the non-users (X2 (2, N = 453) = 32.11, P =
0.000) (Table 1). Moreover, regarding BMI, there were sig-
nificant differences between different groups of PEDs users
(X2 (10, N = 234) = 21.13, P = 0.000) (Figure 1).
4.2. Alcohol Use And History of Aggressiveness
In general, 163 (36%) of participants stated that they
had used alcohol. Again, PED users were more likely to
drink alcoholic beverages (X2 (1, N = 453) = 16.60, P = 0.001)
(Table 2). However, there were no differences regarding al-
cohol use among different class of PED users (X2 (5, 234) =
4.66, P = 0.46). Moreover, 53 (11.7%) of all participants had a
Figure 1. The Average Body Mass Index (BMI) of Each Group of Performance Enhanc-









AAS St AAS+St GH+In+AAS GH+In+AAS+St GH+In+St
Data were shown as mean + SD. AAS: androgenic anabolic steroids, St: stimulants,
GH: growth hormone, In: insulin.
history of violence. Similarly, the PEDs users tended to be
more involved in the aggressive behavior than non-users
(X2(1, N = 453) = 15.88, P = 0.001) (Table 2).
Table 2. The characteristics of male bodybuilding athletesa










184 (78.6) 207 (94.5)
Profes-
sional
50 (21.4) 12 (5.5)
Violence 0.000
Yes 41 (17.5) 12 (5.5)
No 193 (82.5) 207 (94.5)
Alcohol use 0.000
Yes 105 (44.9) 58 (26.5)




Yes 196 (83.8) 153 (63.9)
No 38 (16.2) 66 (30.1)
aRecreational: non-competitive athletes, professional: competitive athletes.
4.3. Characteristics of PEDs Use
According to this study, 234 of bodybuilding athletes
(51.7%) were using or had a history of PED use. The PED
abusers administered an average of 3.80± 4.52 PEDs dur-
ing their routines. Moreover, most of the participants
(70.6%) were single and only 29.4% were married. In this
study, 86.3% of participants were recreational athletes,
while only 13.7% of participants were professional athletes
(Table 2). They used drugs from different classes such as
AASs, stimulants, growth hormone, and insulin. In this
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line, the most prevalent agents used by the participants
were AASs (185 athletes (79.40%)) (Figure 2). Moreover, 110 of
the participants (47.00%) reported stimulant agent admin-
istration during their routines (Figure 2). Furthermore,
professional athletes were more likely to use PEDs in com-
parison with recreational athletes (50 athletes (80.60%) vs.
12 athletes (47.10%), respectively, X2 (1, N = 453) = 24.17, P =
0.000). Moreover, the PED users tended to have more years
of strength training experience than non-users did (6.90±
5.46 vs. 4.74±4.45 years, respectively, P = 0.000) (Figure 3).
Additionally, the PED users underwent strength training
for significantly more hours/week compared to the non-
users (8.79 ± 3.9 vs. 7.64 ± 2.96 hours, respectively, P =
0.001) (Figure 3).












AASs                               st                               GH                           In
Data were shown as percent of participant that used each class of performance
enhancing drugs. AASs: androgenic anabolic steroids; St: stimulant agents; GH:
growth hormone; In: insulin.
The average age of first PEDs use was 23.46± 5.57 years.
The results of this study showed that 165 of the athletes
(71.40%) had used PEDs for the first time before the age of
25. In addition, 66 of bodybuilding athletes (28.60%) ini-
tiated PEDs use after they were 26 years old, while only five
athletes (2.20%) reported onset age of before 15 years. More-
over, the age of first PEDs use was significantly different be-
tween different classes of PED users (P = 0.016). The PED
users had used PEDs for the average of 3.24±4.52 years and
the average PEDs cycle length was 60.67± 38.00 days/year.
Furthermore, the average years of training exercise had di-
rect relation with the length of PEDs use cycle (r (453) = 0.37,
P = 0.000).
Only 92 of PED users (39.50%) had complete knowledge
about the effects of PED use before initiation of use. On
the other hand, 77 of PEDs users (33%) had no information
about PEDs side effects before initiation of PED use (Table
2). Among PED users, only 49 participants (21%) had con-
sulted about the PEDs use, side effects, route and dose of
Figure 3. The Comparison of Training History (year) and Exercise Pattern
(hour/week) of Performance-Enhancing Drugsusers and Non-Users
Data were shown as mean + SD. SP-his: sport (training) history, Excer: exercise pat-
tern. Mann-Whitney U test was used to compare groups. ** shows the significance
level of less than 0.001.
PED administration with a specialist (GP or pharmacist).
In general, only 160 athletes (39.30%) assessed their health
status by regular laboratory testing. Although, PED users
are more likely to use laboratory tests to check for health
than non-users, the difference was not statistically signifi-
cant (X2(1, N = 453) = 3.38, P = 0.077).
The PEDs user participants were asked to disclose the
way of acquaintance with PEDs at the initiation of use. Ac-
cording to them, 116 of PED users (50.00%) had become fa-
miliar with PEDs via their friends before beginning of PED
use. Other than friends, athlete trainers, internet and TV
advertisement had contributed to the acquaintance of ath-












Trainer              Friend            Internet    Advertisment      Others
Figure 4. The Prevalence of Methods That Bodybuilding Athletes Had Used to Be-
come Familiar with the Performance Enhancing Agents
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4.4. Motivation for Use
Our study showed that the primary motivations for
starting PED use by bodybuilding athletes was as followa:
increasing muscle mass (164 PED user athletes (70.10%)),
increasing strength (131 PED user athletes (56%)), weight
gain or loss (95 PEDs user athletes (40.60%)), improving
sport performance (68 PEDs user athletes (29.10%)), increas-
ing endurance (60 PEDs user athletes (25.60%)), improving
physical appearance (43 PEDs user athletes (18.40%)) and
preventing injury (31 PEDs user athletes (13.20%)). More-
over, AAS were the most important factors for increasing
muscle mass, weight gain. On the other hand, stimulants
were mainly used to increase strength, endurance and per-
formance. In addition, the most important motivation for
athletes who used stimulants, GH and insulin together was
losing weight.
4.5. Acquisition
Most of the users (159 athletes (69.40%)) obtained their
AAS supply from local and illicit sources (friends, training
partners, gym members, or dealers); 25 PED user athletes
(10.9%) acquired the drugs from drugstores and 45 users
(19.7%) obtained drugs from both drug stores and illicit
sources.
4.6. Adverse Effects
We asked PED users to report adverse drug effects after
using PEDs. The most prevalent adverse effects reported by
the PED users were sexual effects (increased or decreased
libido, gynecomastia) (49.4%), dermatologic effects (acne,
hair loss, hirsutism) (44.2%), weight gain or loss (37.3%), psy-
chological effects (aggressiveness, anxiety, depression, ner-
vousness, restlessness) (33.0%) and increased or decreased
urination (20.2%). Other side effects such as cardiovascu-
lar effects, damage to the muscles and tendons, delayed
wound healing, infection, jaundice and unknown mass in
the body were reported by the less than 10% of PED users.
Only 23.5% of PED users reported no adverse effects from
PED use.
The prevalence of reported side effects was different
among different groups of PED users. In this regard, the
prevalence of sexual effects (X2 (5, N = 234) = 38.35, P =
0.000), risk of infection (X2 (5, N = 234) = 28.59, P = 0.000),
dermatologic effects (X2 (5, N = 234) = 30.44, P = 0.000), psy-
chiatric effects (X2 (5, N = 234) = 13.24, P = 0.021), weight gain
or loss (X2 (5, N = 234) = 26.95, P = 0.000) and urinary effects
(X2 (5, N = 234) = 11.5, P = 0.042) were significantly different
in the different groups of PEDs users.
4.7. Use of Non-PEDs Dietary Supplements
Participants had used wide range of dietary supple-
ments. The most important dietary supplements that had
been used by the athletes were as follow: protein, amino
acids, glutamine, carbohydrates, and creatine. In gen-
eral, 71.3% of all participants had used legal dietary supple-
ments. It was shown that PED users are much more likely




This study confirmed the high prevalence of PED abuse
among bodybuilding athletes in the south of Iran. Our
study showed that more than half of the bodybuilding ath-
letes had a history of PED use. This rate of PED use is higher
than other studies that investigated PED use among Ira-
nian athletes. In this regard, self-report study had shown
that the probability of lifetime use of AASs in bodybuild-
ing athletes was 24.5% in Kerman (a city of Iran) (15). An-
other study showed that 32.1% of bodybuilders had used
doping agents in Kermanshah (another city of Iran) (16).
This higher prevalence might be related to easier access of
Bushehr athletes to the PEDs that were imported from for-
eign countries. In this regard, high rate of PED acquisition
by the illicit sources in this study may be a proof of this
idea. Moreover, almost all of other studies have focused on
AAS as the most prevalent PEDs of abuse. In contrast, we re-
ported the prevalence of all types of PEDs in the bodybuild-
ing athletes.
According to our study, PED users had significantly
higher BMI in comparison to non-user athletes. Moreover,
only PED users had an average BMI greater than normal
(18.5 - 24.9). In agreement with our study, it was shown
that the AAS users had higher BMIs and body weights than
their non-AAS counterparts, as might be expected due to
the increased lean body mass with AAS administration (14,
17). However, it is possible that overweight or obese ath-
letes have used some PEDs to reduce weight. In line with
this idea, our study showed that the average BMI of ath-
letes who were using GH was higher than only AAS or stim-
ulant users. Moreover, the BMI of non-users was not signif-
icantly different from only AAS or stimulant users. There-
fore, it is possible to assume that losing weight is an im-
portant motivation for athletes to use some PEDs like GH.
In accordance, it was shown that GH administration has
reduced abdominal fat in the abdominally obese men (18)
and might improve social presentation of appearance (14).
In line with this idea, our study showed that the most im-
portant motivation for using GH by the athletes was losing
weight.
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In agreement with other studies (14), the majority of
PED users who participated in our study were recreational
rather than professional athletes. This may imply the
importance of other motivations rather than the perfor-
mance enhancement for using PEDs among bodybuilding
athletes. Likewise, our study showed that increasing mus-
cle mass and strength were more important than improv-
ing performance for especially recreational athletes who
used PEDs. Although, the majority of PEDs users in our
study were recreational athletes, it is noteworthy that pro-
fessional athletes were more likely to be involved in the
PEDs abuse.
5.2. Alcohol Use and History of Aggressiveness
Our study demonstrated high prevalence of alcohol
use among bodybuilding athletes. Moreover, PEDs abusers
were more likely to use alcohol when compared with non-
users. In accordance with our study, it was shown that AASs
use have been involved with the abuse of other illicit drugs
such as alcohol and morphine (19). However, some investi-
gations have reported no differences in alcohol or other il-
licit drug use between PEDs user and non-user athletes (14).
Moreover, it is not completely clear that AASs use increases
the risk of alcohol use or alcohol use raises the likelihood
of AASs abuse (20).
Our study showed that PEDs users in comparison with
non-users were more involved in the violence and aggres-
sive behavior. In line with the present study, it was shown
that the prevalence of aggressive behavior was higher in
AASs user in comparison with non-users (21). Moreover,
this higher representation of aggressive behavior, at least
partly, may be related to the stimulant agent’s abuse or in-
teraction of AASs with stimulants. In this regard, we found
that athletes who used AASs and stimulants together were
more likely to be involved in the aggressive behavior in
comparison to the only AAS or stimulant users.
5.3. Characteristics of PEDs Use
In line with other studies (22), ours showed that mid
20s is the median age of initiation of PED use. It is impor-
tant to notice that the majority of athletes initiated PED
use before the age of 25 while very small numbers of body-
builders reported onset age of PED use before 15. Moreover,
a considerable number of athletes initiated PED use before
the age of 20 (37.7%). In contrast, other studies reported
that 24.8% of western athletes had reported PED use before
the age of 20 (1). This may imply the easier access of Iranian
athletes especially adolescents to the PEDs. Moreover, in
the present study the age of first use of AASs was lower than
stimulant agent’s use. This may be mainly because of the
popularity of AASs among bodybuilding athletes. Further-
more, AASs may be the most available agents in the gyms.
It is important to notice that the majority of athletes
had not had complete knowledge about the effects and ad-
verse effects of PEDs before the initiation of PEDs admin-
istration. Moreover, they did not consult with a pharma-
cist or GP about the administration and effects of these
drugs. In this regard, it was shown that most PED users
did not reveal PED use to any physician (23) mostly because
they did not trust physicians (1). In accordance, they ac-
quired information about PEDs from unsuitable sources.
Another study, in accords with ours, showed that friends
and coaches rather than physicians were the most impor-
tant sources of information about PED administration (10).
Accordingly, it is unfortunate to state that starting PED use
in adolescence without consultation with a physician or
pharmacist and lack of complete knowledge about these
agents may predispose athletes to the risk of serious ad-
verse effects.
Our study indicated that increasing muscle mass, in-
creasing strength and weight gain or loss were the most
important motivations for using PEDs. In accordance with
our study, it was demonstrated that increasing muscle
mass and improving strength were among the most im-
portant motivations for using PEDs specially AASs (14, 22).
Consequently, some of these motivations may reflect the
high rate of AAS use among bodybuilding athletes. In this
regard, Wright and colleagues (2001) (24) have found that
increased muscle mass was the primary motive to use AASs.
In recent decades, social media and cultural expectation
in different parts of the world try to represent men with
a more muscular body (25, 26). Therefore, at the present
time men prefer to look more muscular than their actual
state (27) and according to athletes using PEDs especially
AASs might be the simplest way to achieve this goal.
The participants of our study reported use of about
four agents during their schedules. It was revealed that
polypharmacy was a common practice among bodybuild-
ing athletes who use PEDs (14, 28) that can increase the risk
of adverse effects among PED users (29). In this regard,
76.5% of PED users reported various side effects after ad-
ministration of these agents. Our participants reported
that increasing or decreasing libido, gynecomastia, acne,
hirsutism, hair loss, weight gain or loss and psychologi-
cal effects as the primary adverse effects after administra-
tion of PEDs. In this line, previous studies emphasized on
the role of AAS in producing many of these side effects (1).
Our study confirmed that AAS use increases the likelihood
of sexual and dermatologic side effects. In addition, body-
building athletes who use AAS were more prone to gain
weight. Moreover, athletes who co-administered both AASs
and stimulants reported higher rate of jaundice and psy-
choactive effects in comparison to the only AASs or stimu-
lant users.
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The limitation of these types of retrograde studies is
that information-gathering is based on the participant. In
order to overcome this limitation, we referred athletes to
the lab for measuring follicle-stimulating hormone (FSH)
and luteinizing hormone (LH). However, only about one
third of athletes went to the lab. Therefore, we could not
able to include the confirmed lab results into the study.
In conclusion, this study showed a high rate of PED use
among Iranian bodybuilding athletes, which can expose
them to the various side effects. Moreover, we recommend
evaluating the prevalence of PED use in other sports such
as cycling and wrestling.
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